Discover 729 paid clinical trials in Vancouver, British Columbia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 729
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
for
Withdrawal Syndrome
Location: Surrey
Sponsor: Salem Anaesthesia Pain Clinic
Sex: All
Age: 20 - 70+
Code: NCT05883358
Recruiting
Pain Clinic Provides Public Health Safety
for
Social Functioning, Addiction, Substance, Safety Issues,
Location: Surrey
Sponsor: Salem Anaesthesia Pain Clinic
Sex: All
Age: 20 - 70+
Code: NCT06076512
Recruiting
Pain Clinic Staff Harassed by Patients Pre/Post COVID
for
Patient Violence
Location: Surrey
Sponsor: Salem Anaesthesia Pain Clinic
Sex: All
Age: 20 - 70+
Code: NCT05938101
Recruiting
COVID Infection in Pediatric Surgical Patient
for
COVID-19
Location: Surrey
Sponsor: Salem Anaesthesia Pain Clinic
Sex: All
Age: 2 - 17
Code: NCT05898529
Recruiting
A Community Support Network Intervention in SOAR Project Intimate Partner Violence-Related Traumatic Brain Injury
for
Mild Traumatic Brain Injury
Location: Nanaimo
Sponsor: University of British Columbia
Sex: Female
Age: 18 - 50
Code: NCT04890925
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Location: Abbotsford British Columbia, Olympia WA, Billings MT,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT06758401
Phase3, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),
Location: Abbotsford British Columbia, Spokane WA, Edmonton,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06136650
Phase3, Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2